Literature DB >> 33469068

Prediction of coronary heart disease incidence in a general male population by circulating non-coding small RNA sRNY1-5p in a nested case-control study.

Laurent O Martinez1,2, Michele Trabucchi3, Vera L Costa4, Jean-Bernard Ruidavets5, Vanina Bongard5,6, Bertrand Perret7,8,9, Emanuela Repetto4, Maria G Stathopoulou4, Fabrizio Serra4, Mohamed Benahmed4, Claire Mauduit4, Valerie Grandjean4, Jean Ferrières5,6.   

Abstract

During the development of atherosclerotic lesion, s-RNYs (small RNAs of about 24/34 nucleotides) are derived by the processing of long Ro-associated non-coding RNAs (RNYs) in macrophages. The levels of serum s-RNYs have been found significantly upregulated in patients with coronary heart disease (CHD) compared to age-matched CHD-free individuals. The present study aimed to examine the predictive value of serum s-RNYs for CHD events in the general male population. Within the frame of nested-case-control study, the GENES study, we measured the absolute expression of a RNY-derived small RNA, the s-RNY1-5p, in the serum of individuals (without CHD at baseline) who encountered a CHD event within 12 years of follow-up (n = 30) (Cases) and compared them to individuals who remained event-free (Controls) (n = 30). The expression of s-RNY1-5p in serum was significantly upregulated in Cases compared to Controls (p = 0.027). The proportion of CHD event-free was significantly higher among individuals with serum s-RNY1-5p below the median value (631 molecules/mL). In a multivariable model adjusted for age, smoking, hypertension, diabetes and dyslipidemia, the risk of CHD events increased more than fourfold in individuals with serum s-RNY1-5p above the median value (HR, 4.36; 95% CI 1.22-15.60). A positive association with CHD events was also observed when considering s-RNY1-5p as a continuous variable (p = 0.022). Based on our results, we conclude that serum s-RNY1-5p is an independent predictor of CHD events in a general male population and might be a relevant biomarker for early detection of cardiovascular diseases.

Entities:  

Year:  2021        PMID: 33469068      PMCID: PMC7815790          DOI: 10.1038/s41598-021-81221-8

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  18 in total

Review 1.  Macrophages in atherosclerosis: a dynamic balance.

Authors:  Kathryn J Moore; Frederick J Sheedy; Edward A Fisher
Journal:  Nat Rev Immunol       Date:  2013-09-02       Impact factor: 53.106

Review 2.  The Ro 60 kDa autoantigen comes into focus: interpreting epitope mapping experiments on the basis of structure.

Authors:  Sandra L Wolin; Karin M Reinisch
Journal:  Autoimmun Rev       Date:  2005-11-15       Impact factor: 9.754

Review 3.  Metazoan MicroRNAs.

Authors:  David P Bartel
Journal:  Cell       Date:  2018-03-22       Impact factor: 41.582

4.  Serum IF1 concentration is independently associated to HDL levels and to coronary heart disease: the GENES study.

Authors:  Annelise Genoux; Jean-Bernard Ruidavets; Jean Ferrières; Guillaume Combes; Laeticia Lichtenstein; Véronique Pons; Muriel Laffargue; Dorota Taraszkiewicz; Didier Carrié; Meyer Elbaz; Bertrand Perret; Laurent O Martinez
Journal:  J Lipid Res       Date:  2013-06-21       Impact factor: 5.922

5.  Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.

Authors:  H Tunstall-Pedoe; K Kuulasmaa; P Amouyel; D Arveiler; A M Rajakangas; A Pajak
Journal:  Circulation       Date:  1994-07       Impact factor: 29.690

6.  Mitochondrial inhibitory factor 1 (IF1) is present in human serum and is positively correlated with HDL-cholesterol.

Authors:  Annelise Genoux; Véronique Pons; Claudia Radojkovic; Florence Roux-Dalvai; Guillaume Combes; Corinne Rolland; Nicole Malet; Bernard Monsarrat; Frédéric Lopez; Jean-Bernard Ruidavets; Bertrand Perret; Laurent O Martinez
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

7.  Deep Sequencing of Serum Small RNAs Identifies Patterns of 5' tRNA Half and YRNA Fragment Expression Associated with Breast Cancer.

Authors:  Joseph M Dhahbi; Stephen R Spindler; Hani Atamna; Dario Boffelli; David Ik Martin
Journal:  Biomark Cancer       Date:  2014-12-08

8.  Circulating small non-coding RNA signature in head and neck squamous cell carcinoma.

Authors:  Berta Victoria Martinez; Joseph M Dhahbi; Yury O Nunez Lopez; Katarzyna Lamperska; Paweł Golusinski; Lukasz Luczewski; Tomasz Kolenda; Hani Atamna; Stephen R Spindler; Wojciech Golusinski; Michal M Masternak
Journal:  Oncotarget       Date:  2015-08-07

9.  RNY (YRNA)-derived small RNAs regulate cell death and inflammation in monocytes/macrophages.

Authors:  Zoheir Hizir; Silvia Bottini; Valerie Grandjean; Michele Trabucchi; Emanuela Repetto
Journal:  Cell Death Dis       Date:  2017-01-05       Impact factor: 8.469

10.  RNY-derived small RNAs as a signature of coronary artery disease.

Authors:  Emanuela Repetto; Laeticia Lichtenstein; Zoheir Hizir; Nedra Tekaya; Mohamed Benahmed; Jean-Bernard Ruidavets; Laure-Emmanuelle Zaragosi; Bertrand Perret; Laura Bouchareychas; Annelise Genoux; Romain Lotte; Raymond Ruimy; Jean Ferrières; Pascal Barbry; Laurent O Martinez; Michele Trabucchi
Journal:  BMC Med       Date:  2015-10-08       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.